Omini

Founded in 2019, Omini is developing the first point-of-care blood biomarker monitoring platform to transform the lives of patients suffering from chronic diseases, using its unique multiplex electrochemical biosensor technology. Multiplexing provides personalized blood biomarker data that can be used to adjust therapies and prevent acute crises in patients with chronic conditions. The affordable device combines a portable reader and single-use test strips, similar to a glucometer, simultaneously measuring four to ten blood biomarkers from a single capillary blood sample. It can be used at home or in outpatient care facilities to help relieve the burden on healthcare systems. Omini is currently developing the first application of its solution for heart failure patients, a fast-growing disease nicknamed ‘the silent killer.’